Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not sure where the bottom is here. I'll wait longer...
Phase 3 news- nice. Looks like it'll be relatively inexpensive, and using the 505(b)2 approval pathway, this is likely the only phase 3 data they need to obtain approval.
The volume spike without a massive % shift is encouraging- less likely that scalpers will P&D it. If the direct offering was to non-vultures, this could be the start of a sustained revaluation.
-$
Another RS is definitely a huge concern. I thought they were finally going to move it up after those two press releases in one day, so I averaged down... for the third time. Then they announce the offering. Maybe they're planning something, but that seemed to be one of the dumbest moves I've seen with this stock. It's been really frustrating here!
I'm planning to avg down at some point soon.
Just not sure when. I'm concerned about another RS to stay compliant on Nasdaq.
Pretty pissed off indeed. It's brutal. Hopefully something good happens one of these days, and my average isn't too high to get out with a marginal loss!
And the slow bleeding continues... WTF
I'm pretty pissed off today, but I'm hopeful that this is being done now because they're confident that soon-to-release news will propel the stock above $1 for good, and without the warrants out of the way this might have sufficiently sustained to regain compliance.
I can't say I completely understand this move, and its timing. Yet. Giving a >55% discount to vulturea does appear to show zero regard for longterm shareholder value, which directly contradicts recent claims Lynn has made that longterm shareholder value is a top company priority.
-$
Complete disregard for shareholders here, IMO. Who does press releases, gets the price up and immediately brings it back down? Shift-4, your posts are very insightful - what are your thoughts?
Why couldn't they wait a month or 2 and let the stock price get above $1. Then raise money. So annoying.
Ensysce Biosciences (NASDAQ:ENSC) has announced a $5 million concurrent registered direct offering and exercise of warrants. The company will issue and sell 3,553,194 shares of common stock at $0.47 per share. Additionally, certain outstanding warrants to purchase 7,203,504 shares will be exercised at a reduced price of $0.47 per share. In a private placement, Ensysce will issue unregistered Series A-3 and A-4 warrants to purchase up to 14,358,450 shares each. The offerings are expected to close around August 29, 2024. H.C. Wainwright & Co. is the exclusive placement agent. Ensysce plans to use the proceeds for developing its TAAP and MPAR programs and for working capital, supplementing a recent $14 million NIH grant for PF614-MPAR development.
Thanks Shift
Funny, I found this totally by accident looking for another ticker and started digging into it. Mostly intrigued by the chart and how high the stock was only a few years ago and how beat down it was. Even with the RS the valuation was crazy high. So lots of room to run.
They just announced an offering...
I truthfully don't think the shorts understand any better than demoralized longs do, the power that the expiration of the GEM agreement had on the downside pressure. It's an invisible release, and it's only becoming obvious now that the bottom isn't infinite (as it's seemed for so long).
The emperor has no clothes- they're being exposed right now for continuing to play the game as it went before. But the pattern is broken, and they don't have infinite downside pressure anymore.
They're getting exposed as we speak, and I expect it to continue. It's going to take time for this stock to ripen fully, but it's so severely undervalued that even just the rebound will be highly profitable.
I maintain that this is a buyout candidate more than anything- we likely won't see it bring itself to the promised land of its full potential. But there is huge value in where we are, even now.
-$
I told you man, this is a winner. It requires patience.
I don't know what your situation is- I don't fault anyone for a good scalp. I don't. But if you have the patience to ride this (given your entry), you can do quite well for yourself here.
I fully intend to. Please feel free anytime to reach out. I don't have PM privileges outside of friday, but feel free to reply to a random post anytime and I'll give you what I've got.
I hope we all make it. I praise you for seeing a good thing at the moment few did. Props. It won't be an easy, or linear, journey. But we can generate wealth here.
-$
I certainly hope so! The shorts have been a huge problem for this stock.
This is coiling to rocket higher.
At least one institution is loading, and shorts are running out of shares to borrow against.
-$
$ENSC The NIH does not give out these type of grants unless proof, data verification and product quality has been proven. Nice article today , providing volume . See here https://www.accesswire.com/907807/ensysce-biosciences-receives-14-million-nih-grant-for-clinical-development-of-novel-opioid-with-overdose-protection
ENSC: Look out, above, Peeps!!! A TOM-BRADY-LIKE 'comeback' may be in progress for this little ENSC puppy!!! (But then, maybe NOT. Myself, I consult daily with my 'PSYCHIC HOUSE CAT', who told me WHERE this ENSC stock is going today. See said Cat, below, in action --- about 40-minutes ago --- courtesy of my new, Toilet-Selfie-Cam.)
news isnt that great, its the perception of $14M with a small MC
and lower float
ENSC...........................https://stockcharts.com/h-sc/ui?s=ENSC&p=W&b=5&g=0&id=p86431144783
Boom! This is huge!
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection $ENSC https://t.co/UfQ632JJG6
— Health Stocks News (@health_stocks) August 27, 2024
Whoops, I did it, again
Good to know. Thank you. I guess I'll wait and see what happens between now and then. Hopefully they can get the price back up before then.
The earliest they could RS without immediately downgraded listing to OTC is November.
-$
Yup. The 200MA is over $740! One spike in 2021 appears to have hit over $5750. So many reverse splits. I'd like to average down, but there doesn't seem to be a bottom, and who knows when they'll do another RS...
The 5year chart on this stock is bonkers @ 3k. 52 high is 2.06.
Not sure if this is the bottom but I have added to my position here.
Not expecting any corporate updates until after the shortened July 4 week, but we are entering the zone when anticipation runs and Form 4s are on the table.
It's possible we could see PRs or financing 8-ks as early as July 1 or 2, but it'd be slightly preferable that they hold off until the 8th, imo.
-$
Thanks for the info.
I added to my position recently.
So you're saying, a 300-bagger?!? GREAT!!!
The implications of this stock are ridiculous fundamentally speaking, but what has me intrigued is the expiration of the financing restrictions established by GEM Bahamas as a condition of Ensysce's RM with (formerly) LACQ.
The three-year terms of the financing restrictions were established in late December of 2020, but their effective date was July, 2021. It established a revolving line-of-credit with GEM, whereby the company could access up to $60M of capital by issuing shares at 90% of a preceding interval price to GEM Bahamas. This gives GEM a vested interest in shorting the stock relentlessly to ensure that any conversion would result in maximum share allocation (to them) and maximum dilution (to shareholders). The embedded restrictions severely hampered ENSC's ability to secure alternative financing.
The company has run a razor-lean operation to avoid tapping this line of credit, and has been unable to consider other financing offers while the contract is in effect. GEM has rather obviously been running a ruthless naked shorting operation to ensure that any redemption earns them maximum future profit. The July expiration of this arrangement means no more need for either, and I expected the market rebound to begin in anticipation of this. It appears to have begun; I believe it will continue. And I think the company is going to have a lot to reveal to shareholders about what they've been arranging for when the financial handcuffs come off.
There are a large number of significant developments this company could announce which would positively impact the share price. But this key issue is, I believe, the explanation for both the historic devaluation of the stock to truly absurd levels, and also why no previous runs have been sustainable. Its ending marks a new beginning for ENSC, and in my opinion an historic run when the market re-adjusts.
-$
I have a small position here and thinking of adding more. What makes you so bullish?
Nailed it to the day. This play is going to make me a ++millionaire.
-$
In my opinion, this is the time of maximum future opportunity for minimum cost basis.
-$
$ENSC Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
https://www.accesswire.com/viewarticle.aspx?id=829496
What’s next big man
Flipperooni
2.09 FIRST TARGET WORKED...ALL OUT
Followers
|
21
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
502
|
Created
|
04/05/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |